Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.
about
Teratogenic mechanisms of medical drugsReproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability?The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?Antidepressants, anxiolytics, and hypnotics in pregnancy and lactationBipolar disorder in womenDrugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risksModulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalitiesAntidepressant use in pregnancy: a critical review focused on risks and controversiesTreatment of premenstrual dysphoric disorderUse of SSRI and SNRI Antidepressants during Pregnancy: A Population-Based Study from Denmark, Iceland, Norway and SwedenMaternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007.Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy--an epidemiological study using validated EUROCAT data.Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports.Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.Continuing medical education: SSRIs and pregnancy.Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution.Perinatal outcomes of pregnancies complicated by maternal depression with or without selective serotonin reuptake inhibitor therapyPrenatal exposure to serotonin reuptake inhibitors: a case reportAntidepressant use in pregnancy and the risk of cardiac defectsSelective serotonin reuptake inhibitor exposure during early pregnancy and the risk of birth defects.National trends in antidepressant medication treatment among publicly insured pregnant womenReturning to tricyclic antidepressants for depression during childbearing: clinical and dosing challenges.Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence.Antidepressant use in pregnant and postpartum womenUse of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysisLength of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.The Nordic health registers - an important source when evaluating the safety of antidepressants during pregnancy.Pharmacological treatment of unipolar depression during pregnancy and breast-feeding--a clinical overview.Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot.The management of mood disorders in pregnancy: alternatives to antidepressants.Early pregnancy exposure to selective serotonin reuptake inhibitors, risks of major structural malformations, and hypothesized teratogenic mechanisms.Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study.Sibutramine-associated adverse effects: a practical guide for its safe use.Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.Epidemiologic and genetic aspects of spina bifida and other neural tube defects.Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort studyEarly-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.Perinatal depression: implications for child mental healthEffect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes.The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.
P2860
Q22337136-B8CA1FDF-D1EF-43B6-A95B-7ABFE45D23AFQ24650090-FCCB680A-CA88-46FE-96AC-40D4197F492AQ26741187-FC2AC44C-33C4-46E7-B813-8C37B1AE9BB0Q26795384-E0BC8C29-9D64-45C7-8DD6-061D876BD853Q26795404-24249424-DEC5-4A66-ACDE-2524F4402BCEQ26991704-9414E57B-21C0-4F62-A58A-605FA2275630Q27300825-314E90A2-6CB8-4F36-A35B-B04AAD4FEEE7Q28281407-1D2DF5CA-38E1-4BD6-A9A7-14717F5BC273Q28300895-F6F749EC-6C52-49A9-99E7-1E9851A8A9E2Q28551620-73E3815D-3DBC-4712-8E8D-02A38E75DD27Q30620024-00A9B186-0A12-4169-AC4E-7A5BF3A16761Q30855293-3D741775-CCE8-4BBB-8F80-86276902C724Q30979346-D4143728-77A3-49A3-A0DF-BCC22FE59076Q33521786-4E74B5EC-273E-48E3-A256-7245591C7348Q33671166-79082224-932F-477D-B590-9F7987BFEA82Q33736087-C81724B0-2052-4FD4-9BF0-57BC1C52976BQ33745085-5F0C21E7-D9D5-4511-BEE6-DF4D1268EAB4Q33763631-BAF825F6-F6E1-4421-AB6E-7C712135F9EAQ33775616-11522E33-2D33-4A96-9F79-22C593920EAAQ33801507-51C339F2-A499-417B-83A3-0D7E7384629FQ33830556-E1A6DCFF-DF19-486D-A098-3951DB0F08A8Q33976001-75E8B8D5-49DB-4A0C-A11B-29A3A0FEA9E7Q34047430-4794A95A-91BB-4E98-9794-C7FF97DD84EDQ34068023-9B890A3B-C53C-4217-A6EA-A72F43B71577Q34144128-2F01BDFC-D3D5-468A-B75E-A8412A0BC638Q34178991-AD7F53E1-0306-47DB-84AE-176CF9624840Q34240630-4AB184C3-B009-405F-9555-27736B60E990Q34250131-67860592-19A4-47CE-931C-066DFE35C012Q34270366-7B4E4245-2609-494B-B801-8CC62D796996Q34338163-06A326FD-9CE2-4AB0-8336-1F451F84EB30Q34483257-4B0A2EA3-DB5F-4D73-A625-8D6E00974F9DQ34516341-C8CED388-4072-42AD-BC4F-D2A5C226AD97Q34585304-57BA493F-4A78-4C9E-8D35-4D357D105D64Q34590507-93E1BDD0-BFDD-49F1-8CB4-6B3BFE6057B1Q34645951-C0FF4AFE-7B8E-4953-AD76-A567B4C80FECQ34702282-3D4B5240-4155-4D6A-BE71-B72E6C379E58Q34714284-DD3A658B-5637-4EC0-8A2C-9629D6E3ED63Q34870012-03ED1B82-61D4-4B91-9C9E-177F7BA883A0Q34956921-7601E4BA-C207-485C-BF8B-430713F08254Q34981937-177AFDC0-3750-4F21-BC89-E1767BFAE507
P2860
Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Use of selective serotonin-reu ...... and the risk of birth defects.
@en
Use of selective serotonin-reu ...... and the risk of birth defects.
@nl
type
label
Use of selective serotonin-reu ...... and the risk of birth defects.
@en
Use of selective serotonin-reu ...... and the risk of birth defects.
@nl
prefLabel
Use of selective serotonin-reu ...... and the risk of birth defects.
@en
Use of selective serotonin-reu ...... and the risk of birth defects.
@nl
P50
P356
P1476
Use of selective serotonin-reu ...... and the risk of birth defects.
@en
P2093
Richard S Olney
Sura Alwan
P304
P356
10.1056/NEJMOA066584
P407
P577
2007-06-01T00:00:00Z